In 2000, his group showed that this combination led to full and sustained regression of large tumors in a neuroblastoma xenograft model without increase in toxicity, supporting the model that adjuvant treatment with anti-VEGF agents may benefit multiple cancer treatment regimens (19). This evidence concerns the gene VEGFA and cancer.